- Home
- » Tags
- » Insulin glargine
Top View
- Lantus (Insulin Glargine)
- Exenatide Appears to Be the Eti- Sessing Insulin Sensitivity from the Oral Polyposis
- Zealand Initiates First Phase 3 Trial with Dasiglucagon for the Treatment of Severe Hypoglycemia in Diabetes
- Dasiglucagon—A Next-Generation Glucagon Analog
- Semaglutide Subcutaneous Once-Weekly
- Pramlintide Improved Glycemic Control and Reduced Weight in Patients with Type 2 Diabetes Using Basal Insulin
- Albiglutide (TANZEUM) Drug Monograph
- LIXISENATIDE and Iglarlixi (Insulin Glargine/Lixisenatide Fixed-Ratio Combination)
- Positive Phase 2A Results with Microdoses of Dasiglucagon Support Use in a Dual-Hormone Artificial Pancreas System
- NPH (Humulin N), Insulin Glargine (Lantus)
- Insulin Degludec (Tresiba®) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
- (12) United States Patent (10) Patent No.: US 9,694,053 B2 Haack Et Al
- Update on Insulin Therapy: What's Available and When to Use It
- Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
- XULTOPHY These Highlights Do Not Include All the Information Needed to Use 100/3.6 Or Either of the Active Substances Or Any of Its Excipients (4)
- Insulin Glargine U-300 (Toujeo) National Drug Monograph VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives
- Insulin Administration
- Albiglutide Eperzan® for Type 2 Diabetes Mellitus Drug Assessment Report No Weight Loss, No Use DTB Navarre
- Insulin Glargine: a Long Acting Insulin Analog
- Comparison of Insulin Degludec/Insulin
- Suliqua, Frequent Glucose Monitoring and Dose Adjustment May Be Necessary
- (Insulin Lispro) Basaglar (Insulin Glargine) Semglee (Insulin Glargine) Effective January 1, 2021
- Efficacy of Semaglutide in a Subcutaneous and an Oral
- Pharmacodynamics and Pharmacokinetics of Insulin Detemir and Insulin Glargine 300 U/Ml in Healthy Dogs Thesis Presented in Parti
- The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: an Empirical Perspective from Experience in Australia
- One-Year Treatment with Exenatide Improves Beta-Cell Function
- Dulaglutide in Diabetes and Chronic Kidney Disease
- Once-Weekly Dulaglutide Versus Bedtime Insulin Glargine
- INSULIN GLP-1 COMBINATIONS Soliqua (Insulin Glargine and Lixisenatide), Xultophy (Insulin Degludec and Liraglutide)
- Dasiglucagon (Pinn) Presentation at the 77Th Scientific Sessions of the American Diabetes Association (ADA) Indicate Use for Treatment of Severe Hypoglycemia
- Clinical Review Kristen Pluchino, Phd MPH NDA 214231 Zegalogue (Dasiglucagon Injection)
- Phase II Results with Dasiglucagon (ZP4207) Support Its Potential For
- INSULIN GLARGINE INJECTION TOUJEO™ Solostar®
- Lantus, INN-Insulin Glargine
- SOLIQUA 100/33 (Insulin Glargine
- Insulin Glargine (Lantus)
- PRODUCT MONOGRAPH LANTUS® Insulin Glargine Injection
- Insulin Glargine and Lixisenatide Injection
- Levemir ® (Insulin Detemir Injection) 100 Units/Ml
- BYETTA Should Not Be Restarted
- Insulin Degludec/Insulin Aspart Administered Once
- Xultophy 100/3.6 PI
- Type 1 Diabetes and Insulin Management in 2020
- Soliqua Solostar (Insulin Glargine and Lixisenatide) 1 Name of the Medicine
- PRESS RELEASE Adocia Announces Positive Topline Results for the First
- October 2019
- Effects of Combination Therapy with Liraglutide and Insulin Glargine As
- Dulaglutide Versus Insulin Glargine in Patients with Type 2 Diabetes And
- Insulin Detemir Levemir®
- Volume 16, No. 1 January/February 2018
- Insulin Glargine (Lantus) Is the First Insulin Designed to Mimic a Patient’S Basal Insulin Secretion
- Comparison of Insulin Glargine and Liraglutide Added to Oral Agents In
- Insulins and Tier Coverage Chart
- Weekly Dulaglutide Versus Insulin Glargine In
- FDA-Approved
- Effects of Exenatide Versus Insulin Glargine on Body Composition In
- LEVEMIR® (Insulin Detemir [Rdna Origin] Injection)
- Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St
- Albiglutide) for Injection, for Subcutaneous Use Reaction to Albiglutide Or Any of the Product Components
- Victoza (Liraglutide) Injection
- Testimony of Kathleen W. Tregoning Executive Vice President, External Affairs Sanofi
- Therapeutic Class Overview Insulin and Combination Agents
- The U.S. FDA Approves Soliqua™ 100/33 for the Treatment of Adults with Type 2 Diabetes
- How to Inject Lantus with a Vial and Syringe
- Annual Report for 2020
- Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately
- Product Monograph Basaglar™
- Mixing Insulin Glargine with Rapid-Acting Insulin: a Review of the Literature Dana G
- Ozempic (Semaglutide) Rybelsus (Semaglutide) Tablets Soliqua (Insulin Glargine and Lixisenatide) Xultophy (Insulin Degludec and Liraglutide) Effective 01/01/2021
- Download the Lantus Solostar Injection Guide
- Evidencefinder Last Updated May 7, 2020
- Drug Class Review Newer Drugs for the Treatment of Diabetes Mellitus
- Dulaglutide Trulicity TM TM Trulicity PA009ITIN04 Dulaglutide (Recombinant DNA Origin) 0.75 Mg and Mg 1.5 Solution for Injection
- Study Protocol V2.0 04 July